PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

IL-35-producing B cells in gastric cancer patients.

Abstract A significant characteristic of advanced gastric cancer (GC) is immune suppression, which can promote the progression of GC. Interleukin 35 (IL-35) is an immune-suppressing cytokine, and it is generally recognized that this cytokine is secreted by regulatory T (Treg) cells. Recently, studies have found that IL-35 can also be produced by B cells in mice. However, scientific studies reporting that IL-35 is secreted by B cells in humans, specifically in cancer patients, are very rare.Blood samples were collected from 30 healthy controls (HCs) and 50 untreated GC patients, and IL-35-producing B cells in the peripheral blood were investigated. Moreover, Treg cells (CD4CD25CD127), myeloid-derived suppressor cells (MDSCs) (CD14HLA-DR) and other lymphocyte subsets (CD3, CD4, CD8 T cells, activated and memory CD4 T cells, activated CD8 T cells, CD14 monocytes, and IL-10-producing B cells) were also examined.IL-35-producing B cells were significantly upregulated in patients with advanced GC. Furthermore, the frequency of IL-35-producing B cells was positively correlated with the frequencies of Treg cells (CD4CD25CD127), MDSCs (CD14HLA-DR), IL-10-producing B cells, and CD14 monocytes in these GC patients.In summary, the frequency of IL-35-producing B cells is significantly elevated in advanced GC; this outcome implies that this group of B cells may participate in GC progression.
PMID
Related Publications

Interaction with activated monocytes enhances cytokine expression and suppressive activity of human CD4+CD45ro+CD25+CD127(low) regulatory T cells.

The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients.

Increased intratumoral IL-22-producing CD4(+) T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival.

Regulatory T Cells and Myeloid-Derived Suppressor Cells in Patients with Peptic Ulcer and Gastric Cancer.

Vasoactive intestinal peptide induces CD14+HLA-DR‑/low myeloid-derived suppressor cells in gastric cancer.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29742730
OWN - NLM
STAT- MEDLINE
DCOM- 20180516
LR  - 20180516
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 19
DP  - 2018 May
TI  - IL-35-producing B cells in gastric cancer patients.
PG  - e0710
LID - 10.1097/MD.0000000000010710 [doi]
AB  - A significant characteristic of advanced gastric cancer (GC) is immune
      suppression, which can promote the progression of GC. Interleukin 35 (IL-35) is
      an immune-suppressing cytokine, and it is generally recognized that this cytokine
      is secreted by regulatory T (Treg) cells. Recently, studies have found that IL-35
      can also be produced by B cells in mice. However, scientific studies reporting
      that IL-35 is secreted by B cells in humans, specifically in cancer patients, are
      very rare.Blood samples were collected from 30 healthy controls (HCs) and 50
      untreated GC patients, and IL-35-producing B cells in the peripheral blood were
      investigated. Moreover, Treg cells (CD4CD25CD127), myeloid-derived suppressor
      cells (MDSCs) (CD14HLA-DR) and other lymphocyte subsets (CD3, CD4, CD8 T cells,
      activated and memory CD4 T cells, activated CD8 T cells, CD14 monocytes, and
      IL-10-producing B cells) were also examined.IL-35-producing B cells were
      significantly upregulated in patients with advanced GC. Furthermore, the
      frequency of IL-35-producing B cells was positively correlated with the
      frequencies of Treg cells (CD4CD25CD127), MDSCs (CD14HLA-DR), IL-10-producing B
      cells, and CD14 monocytes in these GC patients.In summary, the frequency of
      IL-35-producing B cells is significantly elevated in advanced GC; this outcome
      implies that this group of B cells may participate in GC progression.
FAU - Wang, Ke
AU  - Wang K
AD  - Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou
      University, Zhengzhou.
FAU - Liu, Jianming
AU  - Liu J
AD  - Department of Pharmacology, JiangXi Medical College, Shangrao, China.
FAU - Li, Jiansheng
AU  - Li J
AD  - Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou
      University, Zhengzhou.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Interleukins)
RN  - 0 (Lipopolysaccharide Receptors)
RN  - 0 (interleukin-35, human)
RN  - 130068-27-8 (Interleukin-10)
SB  - AIM
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - B-Lymphocytes/*immunology/*secretion
MH  - Female
MH  - Humans
MH  - Interleukin-10/immunology/secretion
MH  - Interleukins/immunology/*secretion
MH  - Lipopolysaccharide Receptors/blood/immunology
MH  - Male
MH  - Middle Aged
MH  - Monocytes/immunology/secretion
MH  - Myeloid-Derived Suppressor Cells/immunology/secretion
MH  - Stomach Neoplasms/blood/*immunology/*secretion
MH  - T-Lymphocytes, Regulatory/immunology/secretion
MH  - Up-Regulation
EDAT- 2018/05/10 06:00
MHDA- 2018/05/17 06:00
CRDT- 2018/05/10 06:00
PHST- 2018/05/10 06:00 [entrez]
PHST- 2018/05/10 06:00 [pubmed]
PHST- 2018/05/17 06:00 [medline]
AID - 10.1097/MD.0000000000010710 [doi]
AID - 00005792-201805110-00049 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2018 May;97(19):e0710. doi: 10.1097/MD.0000000000010710.